NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News $27.23 +0.22 (+0.81%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$26.51▼$27.6350-Day Range$26.84▼$36.0852-Week Range$23.09▼$42.48Volume790,164 shsAverage Volume949,604 shsMarket Capitalization$2.92 billionP/E RatioN/ADividend YieldN/APrice Target$54.53 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Arrowhead Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside100.3% Upside$54.53 Price TargetShort InterestBearish6.25% of Float Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.32Based on 9 Articles This WeekInsider TradingSelling Shares$2.59 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.67) to ($2.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector348th out of 965 stocksPharmaceutical Preparations Industry148th out of 453 stocks 4.3 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.53, Arrowhead Pharmaceuticals has a forecasted upside of 100.3% from its current price of $27.23.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.25% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 4.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 2.4 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Arrowhead Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,588,802.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions65.98% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -15.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -15.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arrowhead Pharmaceuticals (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Read More ARWR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARWR Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comChristopher Richard Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockSeptember 21, 2023 | benzinga.comArrowhead Pharma Chief Executive Officer Trades $1.62M In Company StockSeptember 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 20, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Coverage Initiated by Analysts at CitigroupSeptember 19, 2023 | msn.comCitigroup Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Neutral RecommendationSeptember 19, 2023 | americanbankingnews.comFinancial Contrast: Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) & Arrowhead Pharmaceuticals (NASDAQ:ARWR)September 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Shockwave Medical (SWAV) and Gilead Sciences (GILD)September 12, 2023 | markets.businessinsider.comChardan Capital Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)September 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 13, 2023 | finance.yahoo.comSwelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 99% over 5 yearsAugust 11, 2023 | seekingalpha.comArrowhead Remains Well-Positioned For RNAi-Based Therapeutic BreakthroughsAugust 9, 2023 | msn.comCantor Fitzgerald Maintains Arrowhead Pharmaceuticals (ARWR) Overweight RecommendationAugust 9, 2023 | seekingalpha.comArrowhead Pharmaceuticals GAAP EPS of -$0.96 misses by $0.37, revenue of $15.83M misses by $29.59MJuly 22, 2023 | msn.comTD Cowen Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Outperform RecommendationJuly 21, 2023 | msn.comB. Riley Securities Reiterates Arrowhead Pharmaceuticals (ARWR) Buy RecommendationJuly 20, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)July 17, 2023 | marketwatch.comArrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-DUX4July 17, 2023 | finance.yahoo.comArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular DystrophyJune 26, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL)June 24, 2023 | finance.yahoo.comArrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver DiseaseJune 14, 2023 | finance.yahoo.comGoldman Sachs Lifts S&P 500 Price Target By 12.5%; Here Are 2 High-Upside Stocks to Play the BounceJune 10, 2023 | finance.yahoo.comARWR - Arrowhead Pharmaceuticals, Inc.June 7, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)June 6, 2023 | msn.comHC Wainwright & Co. Reiterates Arrowhead Pharmaceuticals (ARWR) Buy RecommendationJune 6, 2023 | seekingalpha.comArrowhead: Biotech Innovation On DisplayJune 6, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)June 2, 2023 | msn.comPiper Sandler Maintains Arrowhead Pharmaceuticals (ARWR) Overweight RecommendationSee More Headlines Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Company Calendar Last Earnings8/07/2023Today9/22/2023Fiscal Year End9/30/2023Next Earnings (Estimated)11/27/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees397Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.53 High Stock Price Forecast$90.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+100.3%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,060,000.00 Net Margins-69.38% Pretax Margin-70.12% Return on Equity-42.79% Return on Assets-21.74% Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$256.21 million Price / Sales11.39 Cash FlowN/A Price / Cash FlowN/A Book Value$3.95 per share Price / Book6.89Miscellaneous Outstanding Shares107,193,000Free Float101,833,000Market Cap$2.92 billion OptionableOptionable Beta1.00 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Christopher R. Anzalone Ph.D. (Age 54)CEO, Pres & Director Comp: $1.65MMr. Kenneth A. Myszkowski (Age 57)Chief Financial Officer Comp: $761.55kMr. Patrick O'Brien J.D. (Age 59)PharmD, COO, Gen. Counsel & Sec. Comp: $749.86kDr. James C. Hamilton M.D. (Age 45)MBA, Chief of Discovery & Translational Medicine Comp: $676.81kMs. Tracie OliverChief Commercial OfficerDr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Vincent Anzalone CFAHead of Investor Relations & VPMr. Howard LovyDirector of CommunicationsDr. Mark Seefeld (Age 69)Head of Toxicology & VP Dr. Javier San Martin M.D. (Age 58)Chief Medical Officer More ExecutivesKey CompetitorsAkero TherapeuticsNASDAQ:AKROIndiviorNASDAQ:INDVProthenaNASDAQ:PRTAHUTCHMEDNASDAQ:HCMBausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsChristopher Richard AnzaloneSold 57,755 sharesTotal: $1.62 M ($28.12/share)Wolverine Trading LLCBought 9,700 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemSold 2,121 shares on 8/21/2023Ownership: 0.116%Teachers Retirement System of The State of KentuckyBought 1,745 shares on 8/21/2023Ownership: 0.016%Castleark Management LLCBought 85,690 shares on 8/16/2023Ownership: 0.080%View All Insider TransactionsView All Institutional Transactions ARWR Stock - Frequently Asked Questions Should I buy or sell Arrowhead Pharmaceuticals stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARWR shares. View ARWR analyst ratings or view top-rated stocks. What is Arrowhead Pharmaceuticals' stock price forecast for 2023? 16 Wall Street analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they expect the company's share price to reach $54.53 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price. View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts. How have ARWR shares performed in 2023? Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of the year. Since then, ARWR shares have decreased by 32.9% and is now trading at $27.23. View the best growth stocks for 2023 here. When is Arrowhead Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 27th 2023. View our ARWR earnings forecast. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.38. The biotechnology company had revenue of $15.83 million for the quarter, compared to analyst estimates of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 42.79% and a negative net margin of 69.38%. The business's revenue for the quarter was down 51.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.68) EPS. What ETFs hold Arrowhead Pharmaceuticals' stock? ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), Neuberger Berman Disrupters ETF (NBDS), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and AI Powered Equity ETF (AIEQ). What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD). What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.95%), State Street Corp (5.14%), JPMorgan Chase & Co. (2.69%), Geode Capital Management LLC (2.01%), Credit Suisse AG (1.33%) and Northern Trust Corp (1.21%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien, Tracie Oliver and William D Waddill. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $27.23. How much money does Arrowhead Pharmaceuticals make? Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $2.92 billion and generates $256.21 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. How many employees does Arrowhead Pharmaceuticals have? The company employs 397 workers across the globe. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401. This page (NASDAQ:ARWR) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.